Last reviewed · How we verify
trastuzumab monotherapy
Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.
Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive metastatic breast cancer.
At a glance
| Generic name | trastuzumab monotherapy |
|---|---|
| Also known as | Herceptin |
| Sponsor | Comprehensive Support Project for Oncology Research |
| Drug class | HER2/neu receptor antagonist |
| Target | HER2/neu |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trastuzumab is a monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2/neu). This binding leads to the internalization and degradation of the receptor, which in turn inhibits the proliferation of cancer cells that overexpress HER2/neu. Additionally, trastuzumab can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), further contributing to its anti-tumor effects.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
- Treatment of HER2-positive metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
- Musculoskeletal pain
Key clinical trials
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
- A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (PHASE1, PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (PHASE1, PHASE2)
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (PHASE2)
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trastuzumab monotherapy CI brief — competitive landscape report
- trastuzumab monotherapy updates RSS · CI watch RSS
- Comprehensive Support Project for Oncology Research portfolio CI